Equity Investment Corp Acquires 44,137 Shares of Sanofi (NASDAQ:SNY)

Equity Investment Corp grew its holdings in shares of Sanofi (NASDAQ:SNY) by 1.8% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,450,326 shares of the company’s stock after purchasing an additional 44,137 shares during the period. Sanofi makes up approximately 3.0% of Equity Investment Corp’s investment portfolio, making the stock its 7th largest holding. Equity Investment Corp owned 0.10% of Sanofi worth $135,895,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. Brighton Jones LLC grew its holdings in Sanofi by 52.6% during the fourth quarter. Brighton Jones LLC now owns 5,420 shares of the company’s stock worth $261,000 after acquiring an additional 1,869 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in Sanofi by 8.9% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 151,945 shares of the company’s stock worth $7,328,000 after acquiring an additional 12,440 shares during the period. HighTower Advisors LLC grew its holdings in Sanofi by 3.4% during the fourth quarter. HighTower Advisors LLC now owns 91,071 shares of the company’s stock worth $4,392,000 after acquiring an additional 2,971 shares during the period. Farther Finance Advisors LLC grew its holdings in Sanofi by 30.7% during the fourth quarter. Farther Finance Advisors LLC now owns 3,739 shares of the company’s stock worth $180,000 after acquiring an additional 878 shares during the period. Finally, Envestnet Portfolio Solutions Inc. grew its holdings in Sanofi by 0.5% during the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 112,181 shares of the company’s stock worth $5,411,000 after acquiring an additional 578 shares during the period. 14.04% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages recently weighed in on SNY. Guggenheim reissued a “buy” rating on shares of Sanofi in a research note on Tuesday, June 3rd. Hsbc Global Res raised Sanofi to a “strong-buy” rating in a research note on Monday, April 28th. BNP Paribas began coverage on Sanofi in a research note on Tuesday, April 15th. They issued an “outperform” rating and a $65.00 price target on the stock. Morgan Stanley set a $56.00 price target on Sanofi in a research note on Monday, June 2nd. Finally, Barclays reissued an “overweight” rating on shares of Sanofi in a research note on Wednesday, July 2nd. Three analysts have rated the stock with a hold rating, four have issued a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Sanofi presently has an average rating of “Buy” and a consensus target price of $61.50.

Sanofi Trading Down 0.9%

Shares of NASDAQ SNY opened at $48.12 on Wednesday. Sanofi has a one year low of $45.80 and a one year high of $60.12. The firm has a market capitalization of $118.01 billion, a PE ratio of 17.19, a PEG ratio of 1.11 and a beta of 0.48. The company has a current ratio of 1.37, a quick ratio of 0.69 and a debt-to-equity ratio of 0.16. The business has a 50-day moving average price of $49.83 and a two-hundred day moving average price of $52.10.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings results on Thursday, April 24th. The company reported $0.94 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.90 by $0.04. The business had revenue of $10.41 billion during the quarter, compared to analyst estimates of $9.79 billion. Sanofi had a return on equity of 17.15% and a net margin of 14.56%. The firm’s revenue was down 11.0% on a year-over-year basis. During the same period in the previous year, the company earned $1.78 EPS. As a group, analysts predict that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.